SCHEMBL23014684

SCHEMBL23014684

CCCCCCCCCc1ccccc1-c1nnn[nH]1.N[SH](=O)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
LIPG Q9Y5X9 1/20 0.38
PTPN1 P18031 1/20 0.35
CYSLTR2 Q9NS75 5/20 0.34
CYSLTR1 Q9Y271 5/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
BID P55957 3/20 0.34
MCL1 Q07820 3/20 0.34
BCL2L1 Q07817 2/20 0.34
BAK1 Q16611 2/20 0.34
KAT8 Q9H7Z6 2/20 0.34
TLR8 Q9NR97 1/20 0.34
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6961906 0.92 LIPG (0.44) NR1H2NR1H3LIPGPTPN1CYSLTR2
SCHEMBL27262019 0.92 LIPG (0.44) NR1H2NR1H3LIPGPTPN1CYSLTR2
SCHEMBL6957954 0.92 LIPG (0.44) NR1H2NR1H3LIPGPTPN1CYSLTR2
SCHEMBL6962603 0.87 NR1H2 (0.36) NR1H2NR1H3LIPGMAPTTLR8
SCHEMBL6962835 0.81 ADRA2B (0.33) PPARA
SCHEMBL6955797 0.79 BID (0.38) CYSLTR2CYSLTR1MAPTBIDMCL1
SCHEMBL6956747 0.78 TRPA1 (0.41) TLR8
SCHEMBL6264727 0.78 NR1H2 (0.36) NR1H2NR1H3LIPGCYSLTR2CYSLTR1
SCHEMBL29173160 0.76 LIPG (0.56) NR1H2NR1H3LIPGCYSLTR2CYSLTR1
SCHEMBL24416955 0.75 MAPT (0.40) LIPGMEN1GAAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540115-B2 Inhibitors of phospholipid synthesis and methods of use THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2026-02-03 US disclosed
US-20220315528-A1 INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2022-10-06 US disclosed
WO-2021035031-A1 INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315528-A1 INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE LCAT, AGPAT2, AGPAT5 NR1H2 1019/4885NR1H3 901/4885LIPG 60/4885
US-12540115-B2 Inhibitors of phospholipid synthesis and methods of use LCAT, DGAT1, DGAT2 NR1H2 116/4885NR1H3 121/4885LIPG 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.